| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 5.2K | 11.6% |
| Total Income | 5.2K | 11.6% |
| Expenditure | 4.1K | 9.6% |
| PBT | 1.2K | 44.4% |
| Net Profit | 1.3K | 99.0% |
| OPM | 21.16% | 1.41pp |
| NPM | 25.77% | 11.32pp |
| EPS | 0.90 | 95.7% |
Boston Scientific Reports Q1 2026 Net Sales of $5.203 Billion, Up 11.6%
22 Apr 2026 · 22 Apr, 4:04 pm
Summary
Boston Scientific reported net sales of $5.203 billion for the first quarter of 2026, representing an 11.6 percent increase on a reported basis. GAAP net income attributable to common stockholders was $1.341 billion, or $0.90 per share. Adjusted EPS for the quarter was $0.80 per share. The company is now estimating full year 2026 net sales growth of approximately 7.0 to 8.5 percent on a reported basis and adjusted EPS of $3.34 to $3.41.
Key Highlights
- 1
Boston Scientific generated net sales of $5.203 billion during the first quarter of 2026, an increase of 11.6 percent on a reported basis compared to the prior year period.
- 2
GAAP net income attributable to Boston Scientific common stockholders was $1.341 billion, or $0.90 per share, compared to $674 million, or $0.45 per share, a year ago.
- 3
Adjusted EPS for the first quarter was $0.80 per share, compared to $0.75 per share in the prior year.
- 4
Cardiovascular net sales grew by 13.5 percent reported and 11.2 percent on an operational and organic basis compared to the prior year period.
- 5
Net sales in the Asia-Pacific region increased by 14.7 percent reported and 12.0 percent operational compared to the prior year period.
- 6
The company now estimates net sales growth for the full year 2026 to be approximately 7.0 to 8.5 percent on a reported basis.
- 7
The company estimates adjusted EPS for the full year 2026 to be $3.34 to $3.41.
Management Comments
Mike Mahoney
Our global team and the strength of our category leadership strategy enabled us to deliver solid results this quarter. We remain focused on executing our long-term strategy and advancing our differentiated pipeline to drive meaningful impact for patients, physicians and hospital systems.
Informational and educational content only. Not investment advice.